malignant pleural mesothelioma
GPTKB entity
Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
pleura
|
| gptkbp:associated_with |
fatigue
weight loss pleural effusion |
| gptkbp:caused_by |
asbestos exposure
|
| gptkbp:clinical_trial |
Phase IV
Phase II Phase III Phase I |
| gptkbp:end_of_life |
5-10% at 5 years
|
| gptkbp:first_described_by |
1960s
|
| gptkbp:genetic_diversity |
CDK N2 A deletion
BA P1 mutation N F2 mutation |
| https://www.w3.org/2000/01/rdf-schema#label |
malignant pleural mesothelioma
|
| gptkbp:is_often_used_in |
gptkb:military_officer
construction workers shipyard workers industrial workers |
| gptkbp:number_of_stages |
stage I
stage IV stage II stage III |
| gptkbp:occurs_in |
1-2 cases per million people
|
| gptkbp:research_focus |
gptkb:vaccine
clinical trials targeted therapy |
| gptkbp:risk_factor |
age
smoking gender |
| gptkbp:social_responsibility |
biopsy
poor imaging tests more common in men increased incidence with age mesothelin long latency period soluble mesothelin-related peptides (SMR Ps) |
| gptkbp:symptoms |
fever
chest pain night sweats persistent cough shortness of breath hemoptysis dyspnea swelling in the abdomen |
| gptkbp:treatment |
gptkb:hospital
gptkb:physicist palliative care combination therapy radiation therapy chemotherapy decortication resistance to chemotherapy late diagnosis high recurrence rate limited treatment options nanoparticle therapy pleurectomy |
| gptkbp:bfsParent |
gptkb:Alimta
|
| gptkbp:bfsLayer |
4
|